Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

746 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy.
Shimamura T, Husain SR, Puri RK. Shimamura T, et al. Neurosurg Focus. 2006 Apr 15;20(4):E11. doi: 10.3171/foc.2006.20.4.6. Neurosurg Focus. 2006. PMID: 16709016 Review.
Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy.
Shimamura T, Fujisawa T, Husain SR, Joshi B, Puri RK. Shimamura T, et al. Clin Cancer Res. 2010 Jan 15;16(2):577-86. doi: 10.1158/1078-0432.CCR-09-2015. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068108
Addiction to the IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells.
Tominaga K, Shimamura T, Kimura N, Murayama T, Matsubara D, Kanauchi H, Niida A, Shimizu S, Nishioka K, Tsuji EI, Yano M, Sugano S, Shimono Y, Ishii H, Saya H, Mori M, Akashi K, Tada KI, Ogawa T, Tojo A, Miyano S, Gotoh N. Tominaga K, et al. Oncogene. 2017 Mar 2;36(9):1276-1286. doi: 10.1038/onc.2016.293. Epub 2016 Aug 22. Oncogene. 2017. PMID: 27546618 Free PMC article.
Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer.
Kato S, Kubota K, Shimamura T, Shinohara Y, Kobayashi N, Watanabe S, Yoneda M, Inamori M, Nakamura F, Ishiguro H, Nakaigawa N, Nagashima Y, Taguri M, Kubota Y, Goshima Y, Morita S, Endo I, Maeda S, Nakajima A, Nakagama H. Kato S, et al. Cancer Sci. 2011 Nov;102(11):2029-37. doi: 10.1111/j.1349-7006.2011.02053.x. Epub 2011 Sep 13. Cancer Sci. 2011. PMID: 21812859
Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.
Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, Ying W, Barsoum J, Wong KK, Shapiro GI. Shimamura T, et al. Clin Cancer Res. 2012 Sep 15;18(18):4973-85. doi: 10.1158/1078-0432.CCR-11-2967. Epub 2012 Jul 17. Clin Cancer Res. 2012. PMID: 22806877 Free PMC article.
In mice bearing NCI-H1975 (EGFR L858R/T790M) xenografts, ganetespib was rapidly eliminated from plasma and normal tissues but was maintained in tumor with t(1/2) 58.3 hours, supporting once-weekly dosing experiments, in which ganetespib produced greater tumor growth inhibi …
In mice bearing NCI-H1975 (EGFR L858R/T790M) xenografts, ganetespib was rapidly eliminated from plasma and normal tissues but was maintained …
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, Cohoon TJ, Janne PA, Meyerson M, Hayes DN, Shapiro GI, Shimamura T, Sholl LM, Rodig SJ, Freeman GJ, Hammerman PS, Dranoff G, Wong KK. Akbay EA, et al. Cancer Discov. 2013 Dec;3(12):1355-63. doi: 10.1158/2159-8290.CD-13-0310. Epub 2013 Sep 27. Cancer Discov. 2013. PMID: 24078774 Free PMC article.
We observed decreased CTLs and increased markers of T-cell exhaustion in mouse models of EGFR-driven lung cancer. PD-1 antibody blockade improved the survival of mice with EGFR-driven adenocarcinomas by enhancing effector T-cell function and lowering the levels of t …
We observed decreased CTLs and increased markers of T-cell exhaustion in mouse models of EGFR-driven lung cancer. PD-1 antibody block …
746 results
Jump to page
Feedback